TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04262388

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is a human immunoglobulin G (IgG)1 kappa monoclonal antibody directed against human PD-L1. Durvalumab selectively binds human PD-L1 with high affinity and blocks its ability to bind to PD-1 and cluster of differentiation (CD)80. The fragment crystallizable (Fc) domain of durvalumab contains a triple mutation in the constant domain of the IgG1 heavy chain that reduces binding to the complement component C1q and the Fc gamma receptors responsible for mediating antibody dependent cell mediated cytotoxicity.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is a human immunoglobulin G (IgG)1 kappa monoclonal antibody directed against human PD-L1. Durvalumab selectively binds human PD-L1 with high affinity and blocks its ability to bind to PD-1 and cluster of differentiation (CD)80. The fragment crystallizable (Fc) domain of durvalumab contains a triple mutation in the constant domain of the IgG1 heavy chain that reduces binding to the complement component C1q and the Fc gamma receptors responsible for mediating antibody dependent cell mediated cytotoxicity.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Oleclumab is a human immunoglobulin G1 lambda monoclonal antibody (mAb) with a triple mutation in the heavy chain constant region for reduced effector function. Oleclumab selectively binds to cluster of differentiation 73 (ecto-5'-nucleotidase) (CD73) and inhibits CD73-associated ectonucleotidase activity, thereby inhibiting the CD73-mediated production of immunosuppressive adenosine. Extracellular adenosine contributes to the immunosuppressive effects of both regulatory T cells and myeloid derived suppressor cells, among others. This, in turn, leads to increased antitumor immunity.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Oleclumab is a human immunoglobulin G1 lambda monoclonal antibody (mAb) with a triple mutation in the heavy chain constant region for reduced effector function. Oleclumab selectively binds to cluster of differentiation 73 (ecto-5'-nucleotidase) (CD73) and inhibits CD73-associated ectonucleotidase activity, thereby inhibiting the CD73-mediated production of immunosuppressive adenosine. Extracellular adenosine contributes to the immunosuppressive effects of both regulatory T cells and myeloid derived suppressor cells, among others. This, in turn, leads to increased antitumor immunity.
Study: NCT06324162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bracket removal pliers, LODI
Description: Brackets on the right side of both dental arches were debonded using the lift-off debonding instrument (LODI), while on the left side, the bracket removal pliers (BRP). The residual adhesive was removed through two methods (manual in the upper arch and rotary in the lower). The same scale was employed to assess pain levels during brackets and adhesive removal.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bracket removal pliers, LODI
Description: Brackets on the right side of both dental arches were debonded using the lift-off debonding instrument (LODI), while on the left side, the bracket removal pliers (BRP). The residual adhesive was removed through two methods (manual in the upper arch and rotary in the lower). The same scale was employed to assess pain levels during brackets and adhesive removal.
Study: NCT06161246

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrating Beauty Bar
Description: A vibrating beauty bar will be used at the injection site for patient comfort.
Study: NCT05903898

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI software StrokeSens (Circle NVI)
Description: Computed tomography (CT) and computed tomography angiography (CTA) imaging studies acquired upon admission will be assessed by the AI software StrokeSENS (Circle NVI). StrokeSENS is CE marked and available for clinical diagnostic purposes in the EU and UK.The software will be a decision support tool in addition to standard radiological services available in all primary stroke centers in Northern Norway where image interpretation is done by a radiologist or resident in radiology. The software can automatically evaluate the presence of ischemic changes in the vascular territory of the middle cerebral artery according to the Alberta Stroke Program Early CT Score (ASPECTS) and occlusions in the intracranial segment of the internal carotid artery and the proximal segments of the middle cerebral artery (MCA). Output to radiologists will be automated ASPECT scoring, automated search for LVO or MeVO.
Study: NCT05715099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saffron
Description: Dietary Supplement: saffron supplement for IBD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saffron
Description: Dietary Supplement: saffron supplement for IBD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saffron
Description: Dietary Supplement: saffron supplement for IBD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saffron
Description: Dietary Supplement: saffron supplement for IBD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dietary Supplement: placebo for IBD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dietary Supplement: placebo for IBD
Study: NCT05781906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-523
Description: D1-D7: HMPL-523 Tablet 300 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 µCi [14C]HMPL-523
Description: D8: \[14C\] HMPL-523 Suspension 300 mg/150 μCi Single dose
Study: NCT06058923

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: M-MIST
Description: This is characterized by a vestibular mucoperiosteal envelope flap without relaxing incisions. Sulcular incisions will be made on the vestibular surface of the teeth included in the surgical area, adjacent to the infraosseous defect. The mesiodistal extension of the flap will be kept to a minimum necessary to access the defect. In the papillary area over the infraosseous defect, an oblique or horizontal incision will be made at the level of the interdental papilla, following the contour of the bone crest. The vestibular flap will be elevated, leaving the lingual/palatal portion adhered, only to allow access to the bone defect. The defect will be instrumented with mini-curettes and specific ultrasonic tips, and the defect will be filled only with a blood clot after this procedure. Primary closure will be achieved with internal vertical and/or horizontal mattress sutures, which may be complemented with simple sutures, all using specific suture threads.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MIST
Description: A vestibular envelope flap, without vertical relaxing incisions, will be raised on the vestibular and lingual/palatal sides. Primary intrasulcular incisions will be made to the alveolar crest, encompassing the teeth included in the surgical area. In the interproximal area, incisions will follow the principle of preserving the papilla (Modified Papilla Preservation Technique = MPPT or Simplified Papilla Preservation Flap = SPPF), depending on the available interproximal space (Cortellini et al., 1995, 1999). The mesiodistal extension of the flap will be minimized to provide adequate access to the defect. The defect will be instrumented using mini-curettes and specific ultrasonic tips, and the defect will be filled only with a blood clot after these procedures. Flap closure will be achieved with internal horizontal and/or vertical mattress sutures, which may be modified or complemented with simple sutures, all using specific suture threads.
Study: NCT04725773

Intervention type: DEVICE
Intervention: Deep brain stimulation effect on apraxia
Description: We will evaluate the effect of DBS on apraxia
Study: NCT06554795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1419
Description: Administered Injection of Vein (I.V.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1419
Description: Administered Injection of Vein (I.V.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1419
Description: Administered Injection of Vein (I.V.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1419
Description: Administered Injection of Vein (I.V.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1419
Description: Administered Injection of Vein (I.V.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1419
Description: Administered Injection of Vein (I.V.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1419
Description: Administered Injection of Vein (I.V.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1419
Description: Administered Injection of Vein (I.V.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1419
Description: Administered Injection of Vein (I.V.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1419
Description: Administered Injection of Vein (I.V.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1419
Description: Administered Injection of Vein (I.V.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1419
Description: Administered Injection of Vein (I.V.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1419
Description: Administered Injection of Vein (I.V.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1419
Description: Administered Injection of Vein (I.V.)
Study: NCT05098834

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENLIGHT 2100 ventilatory electrical impedance tomograph
Description: The ENLIGHT 2100 system will remain connected to the patient for data acquisition from immediately prior to initiation of the ERT until up to 24 hours following extubation.
Study: NCT05179928

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block (ESPB)
Description: Postoperative Bilateral Ultrasound-guided ESPB

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectus Sheath Block (RSB)
Description: Postoperative Bilateral Ultrasound-guided RSB
Study: NCT06470555

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A figure-of-eight suture secured with a three-way tap
Description: Femoral haemostasis using a figure-of-eight suture technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A figure-of-eight suture secured with a three-way tap
Description: Femoral haemostasis using a figure-of-eight suture technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shortened bed rest duration of 2-hours
Description: Bed rest duration of 2-hours after initial haemostasis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual compression
Description: Femoral haemostasis using manual compression

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional bed rest duration of 4-hours
Description: Bed rest duration of 4-hours after initial haemostasis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional bed rest duration of 4-hours
Description: Bed rest duration of 4-hours after initial haemostasis
Study: NCT05199337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-d5
Description: ZN-d5 will be administered orally
Study: NCT05082610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMBD-002
Description: IgG4 monoclonal antibody (mAb) targeting the V-domain immunoglobulin suppressor of T cell activation (VISTA) receptor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMBD-002
Description: IgG4 monoclonal antibody (mAb) targeting the V-domain immunoglobulin suppressor of T cell activation (VISTA) receptor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMBD-002
Description: IgG4 monoclonal antibody (mAb) targeting the V-domain immunoglobulin suppressor of T cell activation (VISTA) receptor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMBD-002
Description: IgG4 monoclonal antibody (mAb) targeting the V-domain immunoglobulin suppressor of T cell activation (VISTA) receptor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IgG4 mAb with high specificity of binding to the PD-1 receptor, thus inhibiting its interaction with PD-L1 and programmed cell death ligand 2 (PD-L2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IgG4 mAb with high specificity of binding to the PD-1 receptor, thus inhibiting its interaction with PD-L1 and programmed cell death ligand 2 (PD-L2).
Study: NCT05820932

Intervention type: GENETIC
Intervention: Blood-based assay
Description: Blood samples will be collected

Intervention type: GENETIC
Intervention: Blood-based assay
Description: Blood samples will be collected

Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive assessments
Description: Cognitive assessments will be both participant- and partner-reported

Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive assessments
Description: Cognitive assessments will be both participant- and partner-reported

Intervention type: OTHER
Intervention: Quality of Life Surveys
Description: Participant-reported Quality of Life Surveys

Intervention type: OTHER
Intervention: Quality of Life Surveys
Description: Participant-reported Quality of Life Surveys

Intervention type: OTHER
Intervention: Quality of Life Surveys
Description: Participant-reported Quality of Life Surveys
Study: NCT06388512

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: prototype prone positioning device
Description: The prototype prone positioning device will be used during neurosurgical procedures utilizing intraoperative MRI.
Study: NCT05782023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital empowerment
Description: The intervention will consist of a minimal interaction face-to-face before hospital discharge for risk factors profiling followed by actions for health empowerment, delivered through an ad-hoc developed web platform, which include: a) periodic delivery of email messages with links to educational, motivational and supportive materials for secondary prevention, b) access to a message box for questions and answers and c) possibility of video-calls with the preventive team.
Study: NCT04733521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC-43
Description: SC-43 oral, every day of 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC-43
Description: SC-43 oral, every day of 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: cisplatin 75mg/m2 on day 1 of 21-day cycle
Study: NCT04282161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Axys EX device
Description: Rotational atherectomy system for endovascular treatment of peripheral arterial disease prior to adjunctive therapy, if needed
Study: NCT05516381

Intervention type: DEVICE
Group type: OTHER
Intervention: Optetrak Logic CR Knee System
Description: The OPTETRAK® Comprehensive Knee System consists of the OPTETRAK® Total Knee System and the OPTETRAK Logic® Total Knee System. The OPTETRAK Comprehensive Knee System comprises both non-porous and porous knee prostheses for use in total-knee joint replacement procedures. (In the USA, the OPTETRAK Comprehensive Knee System is indicated for cemented use only, except for the OPTETRAK Logic PS and CR Porous Femoral Components, which are indicated for cemented or cementless use.) The system includes various sizes and types of modular femoral components, tibial components, patellar components, and accessories for use in primary and revision applications.

Intervention type: DEVICE
Group type: OTHER
Intervention: Optetrak Logic CR Knee System
Description: The OPTETRAK® Comprehensive Knee System consists of the OPTETRAK® Total Knee System and the OPTETRAK Logic® Total Knee System. The OPTETRAK Comprehensive Knee System comprises both non-porous and porous knee prostheses for use in total-knee joint replacement procedures. (In the USA, the OPTETRAK Comprehensive Knee System is indicated for cemented use only, except for the OPTETRAK Logic PS and CR Porous Femoral Components, which are indicated for cemented or cementless use.) The system includes various sizes and types of modular femoral components, tibial components, patellar components, and accessories for use in primary and revision applications.
Study: NCT05707728

Intervention type: DEVICE
Intervention: intraoperative ultrasound
Description: intraoperative cranial ultrasound
Study: NCT05736380

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cerebellar rTMS
Description: 250 pulses at 10 Hertz over the cerebellum

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham cerebellar rTMS
Description: Sham cerebellar rTMS
Study: NCT04733521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: cisplatin 75mg/m2 on day 1 of 21-day cycle
Study: NCT05523453

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Processing of Positive Memories Technique (PPMT)
Description: PPMT comprises of 5 sessions focused on identifying and processing positive memories. In Session 1-5, participants narrate details of one positive memory, and process the positive memory to elicit positive values, affect, strengths, and thoughts.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Counseling (SC)
Description: SC is a 5-session, active and non-specific treatment administered weekly, which includes a discussion of the daily monitoring diary and exploration of current issues and concerns.
Study: NCT05479877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sterile medicated collagen particles, Biofil-AB ,Eucare Pharmaceuticals Pvt. Ltd, Chennai, India
Description: Collagen based pulpotomy will be applied (sterile medicated collagen particles, Biofil-AB ,Eucare Pharmaceuticals Pvt. Ltd, Chennai, India)according to the manufacturer's instructions and gently placed over the pulp stumps to a thickness of 2 mm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biodentine (Septodont, Saint-Maur-des-Fossés, France)
Description: Biodentine (Septodont, Saint-Maur-des-Fossés, France) will be applied according to the manufacturer's instructions and placed over the radicular pulp with the help of a suitable sterile amalgam carrier. Gentle condensation of the mix will be done in the pulp chamber with a moistened cotton pellet.
Study: NCT05127954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubrogepant
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubrogepant
Description: Oral Tablet
Study: NCT06474247

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Postbiotic
Description: Postbiotic at 1g/day as an adjunct treatment against vaginal candidiasis in women for 4-weeks

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo at 1g/day as an adjunct treatment against vaginal candidiasis in women for 4-weeks
Study: NCT05947357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition Assistance Program
Description: Patients will receive in the intervention group a $40.00 per month voucher for 6 months for use in the produce section of a local grocery store.
Study: NCT05397925

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADSProgram - Self management for substance dependence program
Description: GENERAL STRUCTURE OF THE MODEL - 8 sessions: One initial - assessment; 1 to 6 Intermediates - empowerment (Flexible number of intermediate sessions according to the person's need and accessibility, interlude 1 week minimum, up to a maximum of 3 weeks); 1 Final - autonomy; Duration of sessions: 20-60 min; Context: Outpatient specialized addictions unit. Private room needed; Preferred approach: Individual, face-to-face or virtual consultation. Complementary approach: In groups of up to 4 people, when peer support or sharing feelings are needed: Clinical focus 1 - Concerning the problematic use of substances, 2 - Related to health knowledge in general, 3 - Related to health-seeking behavior and adherence, 4 - Related to self-knowledge and well-being, 5 - Related to social role and personal dignity, 6 - Related to the family process.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual - Regular nursing consultation on a medication-based program
Description: Regular individual assessment on: substance used (kind of substance, consumption way, frequency), way of living, social relationship, health status nursing diagnoses. To support on this, therapeutic interventions, medication delivery and management support.
Study: NCT05023642

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistance training
Description: Interventions will include a three-phase strengthening training protocol.~1. Adaptation phase: three sessions, emphasis on learning the technique, body self-awareness, and movement coordination;~2. Basic phase: 12 sessions, to increase muscle strength; and~3. Specific phase: 21 sessions, to intensify the process of strength gain and muscular hypertrophy.~Participants will perform the following exercises during the strength-training protocol intervention: pec deck/seated lever fly, adductor, pulldown, abductor strengthening, alternating dumbbell curl, leg press at a 45-angle, triceps pulley, lateral raise, knee flexion and extension, ankle joint flexion and extension in the leg press, and crunches. If the participant has difficulty performing a specific exercise, an equivalent activity will replace it. From the eighth week onwards, participants will perform additional exercises focused on strengthening the gastrocnemius and soleus.
Study: NCT05628064

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1C70
Description: Investigational energy storage and return prosthetic foot with using novel elastic elements.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1C70
Description: Investigational energy storage and return prosthetic foot with using novel elastic elements.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pro-Flex XC
Description: Commercially available carbon-fiber energy storage and return foot used as comparative foot for transtibial amputee subjects.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pro-Flex XC
Description: Commercially available carbon-fiber energy storage and return foot used as comparative foot for transtibial amputee subjects.
Study: NCT06436131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-phase Bilateral Exercise
Description: The exercise program of the experimental group consisted of exercises based on in-phase bilateral movements of the upper and lower limbs, which were adapted to different sport activities and to fitness functional exercises.~The participants of experimental group performed the specific type exercises three times per week, for 12 consecutive weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conservative exercises
Description: The participants of the active control group, underwent an exercise program based on conventional exercises, such as strengthening of the major muscle groups of the trunk, resistance exercises for the upper and lower limbs and body weight support treadmill exercise.